U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 11 - 20 of 1,060 results

Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (EPIMERIC)



ODM-201 (also known as BAY-1841788) is a non-steroidal antiandrogen, specifically, a full and high-affinity antagonist of the androgen receptor (AR), that is under development by Orion and Bayer HealthCare for the treatment of advanced, castration-re...
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ABSOLUTE)


ADX-N05, originally discovered by SK Holdings, is a selective dopamine and norepinephrine reuptake inhibitor (DNRI). ADX-N05 (Solriamfetol, sold under the brand name Sunosi) is approved in the US and is under regulatory review in the EU to improve wa...
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ACHIRAL)



Siponimod (BAF312) is a dual agonist at the sphingosine-1 phosphate receptors, S1PR1 and S1PR5. The S1P receptor is commonly found on the surface of specific cells residing in the central nervous system (CNS), that are responsible for causing CNS dam...
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ACHIRAL)



Pitolisant (INN) or tiprolisant (USAN) is a histamine receptor inverse agonist/antagonist selective for the H3 subtype. It has stimulant and nootropic effects in animal studies and may have several medical applications, having been researched for the...
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ACHIRAL)


LASMIDITAN is a serotonin (5-HT) receptor agonist without vasoconstrictor activity, which selectively binds to the 5-HT(1F) receptor subtype. It is under development for the treatment of migraine.
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ACHIRAL)



Triclabendazole, (brand name Avomec, Egaten, etc) is a member of the benzimidazole family of anthelmintics used to treat liver flukes, specifically fascioliasis and paragonimiasis. Triclabendazole used routinely since 1983 in veterinary practice for ...
Status:
US Approved Rx (2025)
First approved in 2018

Class (Stereo):
CHEMICAL (RACEMIC)



Lofexidine is newly FDA approved in the United States under the brand name LUCEMYRA for the treatment of opioid withdrawal symptoms in adults. Lofexidine acts as an agonist to α2 adrenergic receptors. These receptors inhibit adenylyl cyclase activity...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Tafenoquine is anti-malaria drug originated in Walter reed army institute of research and developed by GSK and 60 Degrees Pharmaceuticals. In 2018 United States Food and Drug Administration (FDA) approved single dose tafenoquine for the radical cure ...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Migalastat (Galafold)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations. Mi...

Showing 11 - 20 of 1,060 results